动物造模,哮喘小鼠模型 zi-bio 2024-03-06 518

　　Objective: To observe the role of interleukin-22 (IL-22) in asthma models and study the regulatory effects of budesonide on airway inflammation and IL-22 in asthma mouse models.

　　Method: 24 BALB/c mice were randomly divided into three groups: control group, asthma model group, and budesonide group. Asthma models were prepared by sensitization and stimulation of mice with ovalbumin (OVA). HE and AB-PAS staining were performed on mouse lung tissue to evaluate airway inflammation. ELISA was used to detect the level of IL-22 in BALF of three groups of mice, and real-time fluorescence quantitative PCR was used to detect the expression level of IL-22mRNA in mouse lung tissue.

　　Result: Compared with the control group, asthma mice showed an increase in lung tissue inflammation score, IL-22 levels in BALF, and IL-22mRNA expression levels in lung tissue, all of which were statistically significant. After treatment with budesonide, the airway inflammation score and the expression level of IL-22mRNA in lung tissue of mice decreased compared to the asthma group, and the difference was statistically significant.

　　Conclusion: The therapeutic effect of budesonide on asthma airway inflammation is related to its inhibition of the expression and secretion of IL-22 in the lungs.